Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

S Kubicka; Richard Greil; T Andre; J Bennouna; J Sastre; E Van Cutsem; R Von Moos; PJ Osterlund; P Hegde; MA Sersch; S Osborne; F Hermann; D Arnold

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

S Kubicka, Richard Greil, T Andre, J Bennouna, J Sastre, E Van Cutsem, R Von Moos, PJ Osterlund, P Hegde, MA Sersch, S Osborne, F Hermann, D Arnold

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	32
Issue number	3
Publication status	Published - 2014
Event	Gastrointestinal Cancers Symposium - San Francisco, CA Duration: 16 Jan 2014 → 18 Jan 2014

Cite this

Kubicka, S., Greil, R., Andre, T., Bennouna, J., Sastre, J., Van Cutsem, E., Von Moos, R., Osterlund, PJ., Hegde, P., Sersch, MA., Osborne, S., Hermann, F., & Arnold, D. (2014). Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. JOURNAL OF CLINICAL ONCOLOGY , 32(3).

Kubicka, S ; Greil, Richard ; Andre, T et al. / Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. In: JOURNAL OF CLINICAL ONCOLOGY 2014 ; Vol. 32, No. 3.

@article{e02d291492ce4184b1559dfc0bfcbf27,

title = "Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.",

author = "S Kubicka and Richard Greil and T Andre and J Bennouna and J Sastre and {Van Cutsem}, E and {Von Moos}, R and PJ Osterlund and P Hegde and MA Sersch and S Osborne and F Hermann and D Arnold",

year = "2014",

language = "English",

volume = "32",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "3",

note = "Gastrointestinal Cancers Symposium ; Conference date: 16-01-2014 Through 18-01-2014",

}

Kubicka, S, Greil, R, Andre, T, Bennouna, J, Sastre, J, Van Cutsem, E, Von Moos, R, Osterlund, PJ, Hegde, P, Sersch, MA, Osborne, S, Hermann, F & Arnold, D 2014, 'Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.', JOURNAL OF CLINICAL ONCOLOGY , vol. 32, no. 3.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. / Kubicka, S; Greil, Richard; Andre, T et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 32, No. 3, 2014.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

AU - Kubicka, S

AU - Greil, Richard

AU - Andre, T

AU - Bennouna, J

AU - Sastre, J

AU - Van Cutsem, E

AU - Von Moos, R

AU - Osterlund, PJ

AU - Hegde, P

AU - Sersch, MA

AU - Osborne, S

AU - Hermann, F

AU - Arnold, D

PY - 2014

Y1 - 2014

M3 - Abstract (Journal)

SN - 0732-183X

VL - 32

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 3

T2 - Gastrointestinal Cancers Symposium

Y2 - 16 January 2014 through 18 January 2014

ER -

Kubicka S, Greil R, Andre T, Bennouna J, Sastre J, Van Cutsem E et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study. JOURNAL OF CLINICAL ONCOLOGY . 2014;32(3).